Palivizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus (RSV)
Conditions
Respiratory Syncytial Virus (RSV)
Trial Timeline
Nov 9, 2016 → Jul 13, 2017
NCT ID
NCT02968173About Palivizumab
Palivizumab is a phase 3 stage product being developed by AbbVie for Respiratory Syncytial Virus (RSV). The current trial status is completed. This product is registered under clinical trial identifier NCT02968173. Target conditions include Respiratory Syncytial Virus (RSV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02968173 | Phase 3 | Completed |
| NCT01466062 | Phase 3 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus (RSV)